2025 AACR Annual Meeting Perioperative Pembrolizumab Plus Standard of Care for Resectable Locally Advanced HNSCC
Breast Cancer Addition of Sacituzumab Govitecan to Pembrolizumab in Advanced Triple-Negative Breast Cancer